Table 1.
SCI subjects’ characteristics
| Subjects | Gender | Age (years) | Post-injury (months) | Ashworth score | ASIA scale | Lesion level | Sensation | Medication/day |
|---|---|---|---|---|---|---|---|---|
| S1 | M | 23 | 72 | 1 | C | C5 | Intact | – |
| S2 | M | 44 | 9 | 0 | B | C5 | Intact | Vallium 30 mg |
| S3 | M | 27 | 20 | 0 | C | C5 | Intact | – |
| S4 | M | 45 | 48 | 2 | C | C6 | Intact | Baclofen 60 mg |
| S5 | M | 20 | 15 | 2 | C | T11 | Intact | Baclofen 20 mg |
| S6 | M | 17 | 21 | 0 | D | C6 | Intact | Baclofen 20 mg |
| S7 | F | 59 | 20 | 0 | C | T9 | Intact | Baclofen 10 mg |
| S8 | M | 15 | 20 | 2 | C | T3 | No sensation of cold/warm | – |
| S9 | M | 42 | 32 | 0 | C | C8 | Intact | Plavix Lipotor 75 mg |
| S10 | M | 50 | 180 | 1 | C | C5 | No sensation of cold/warm | Baclofen 30 mg |
| S11 | M | 50 | 156 | 3 | C | C5 | No sensation of cold/warm | – |
Spasticity at the ankle was scaled according to the Ashworth scale (Ashworth 1964). The completeness of the lesion was classified according to the American Spinal Injury Association (ASIA) scale (Maynard et al. 1997), ASIA B motor complete but sensory incomplete, ASIA C sensory and motor incomplete, but with more than half of muscles below injury level having a muscle grade (estimated via manual muscle test) of less than 3 out of 5 ASIA D sensory and motor incomplete with at least half of the muscles below the level of the injury having a muscle grade of 3 or higher. F Female, M Male